Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?

Por Martin Glas, Sied Kebir
Publicado em 2019-12-01

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Por Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Armin Scheffler
Publicado em 2022-05-01

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Por Armin Scheffler, Olga Messel, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Steffen Naegel, Dagny Holle
Publicado em 2020-07-01

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12

Por Frank A. Giordano, Barbara Link, Martin Glas, Ulrich Herrlinger, Frederik Wenz, Viktor Umansky, J. Martin Brown, Carsten Herskind
Publicado em 2019-02-01

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature

Por Theophilos Tzaridis, Katrin S Reiners, Johannes Weller, Daniel Bachurski, Niklas Schäfer, Christina Schaub, Michael Hallek, Björn Scheffler, Martin Glas, Ulrich Herrlinger, Stefan Wild, Christoph Coch, Gunther Hartmann
Publicado em 2020-09-01

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells

Por Jonas Feldheim, Almuth F. Kessler, Julia J. Feldheim, Ellina Schulz, David Wend, Lazaros Lazaridis, Christoph Kleinschnitz, Martin Glas, Ralf-Ingo Ernestus, Sebastian Brandner, Camelia M. Monoranu, Mario Löhr, Carsten Hagemann
Publicado em 2022-05-01